9 results about "RNA polymerase II" patented technology

The invention discloses a tool for realizing efficient specific gene inhibition in a plant by utilizing a SunTag system of CRISPR-dCas9 (clustered regularly interspaced short palindromic repeats-das9). According to the method, gRNA near a transcription start site of a targeted target gene is designed, dCas9 and scFv-GFP are accurately recruited to a target site by using a SunTag system, the transcription start process of RNA polymerase II is interfered, and the expression of the target gene is remarkably inhibited. In view of relatively high activity of the system in a plant rdr6 mutant, an artificial miR-RDR6 fragment is further introduced into a vector and is used for inhibiting expression of RDR6 in a wild plant, so that the applicability and functionality of the system are expanded. Compared with a traditional method depending on a plant endogenous effector, the method has the advantages that dependence on endogenous regulatory factors is avoided, the specificity and safety of gene inhibition are remarkably improved, and the method can be used for plant genetic function research and character improvement.

The invention discloses a plukenetia volubilis FAD2 gene promoter. The nucleotide sequence of the plukenetia volubilis FAD2 gene promoter proPvFAD2.4 is shown in the specification. The proPvFAD2.4 comprises TATA-box and CAAT-box, and the TATA-box and the CAAT-box are located at the upstream of a transcription start site (TSS), so that basic transcription support is provided for positioning of RNA polymerase II, and the basic expression level of the gene is ensured. Comprising seed specific elements of AE-box and O2-site, and specific expression of PvFAD2 in the seed development stage is combined with DOF (OBP2) and MADS-box transcription factors to drive grease to be quickly accumulated. And the recombinant plasmid vector has a strong starting effect, so that the promoter has a function of starting downstream gene expression in a tobacco leaf cell environment, and an experimental foundation is laid for subsequent analysis of a regulation mechanism of the promoter.

The present application relates to an oil palm UBQ promoter and application thereof, and belongs to the technical field of biology.The nucleic acid sequence of the promoter is shown as SEQ ID NO.1, the present application firstly aligns and intercepts a sequence of 2000bp upstream of a start codon in an oil palm genome, and synthesizes an oil palm RNA polymerase II type promoter, i.e., an oil palm endogenous ubiquitin promoter EgUBQ.The promoter has transcription activity, and can drive expression of downstream green fluorescent protein NeonGreen.The present application provides an oil palm endogenous UBQ promoter for genetic transformation and gene editing of oil palm.

Embodiments herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies, such as sickle cell disease or thalassemia, by increasing the expression levels of fetal hemoglobin levels.

The present disclosure unravels novel mechanistic information involving the direct regulation of OBSCN via OBSCN-AS1 through chromatin remodeling and enhanced RNA polymerase II recruitment. Remarkably, it is shown herein that targeting of OBSCN-AS1 is sufficient to restore OBSCN expression in highly aggressive triple-negative breast cancer cells. Provided herein are methods for increasing OBSCN expression in a cell, comprising providing to the cell one or more agents that increases levels of OBSCN-AS1 IncRNA or a variant thereof in the cell, and CRISPR / Cas9 systems for increasing levels of OBSCN-AS1 IncRNA in cells.

The invention provides a urine protein marker related to biliary tract cancer immunotherapy and application of the urine protein marker, and belongs to the technical field of biomedicine. The urine protein marker related to biliary tract cancer immunotherapy comprises a non-receptor tyrosine phosphatase 13 type (PTPN13), an activation RNA polymerase II transcription coactivator p15 (SUB1), an MICAL-like 1 protein (MICALL1) and a valyl-tRNA synthetase 1 (VARS1), and a combination established by the four urine proteins can be used for predicting the curative effect and (or) prognosis of the biliary tract cancer immunotherapy. One or more of the four urine protein markers can be used for prediction and / or prognosis analysis of the immunotherapy curative effect of the biliary tract cancer through mass spectrometric detection or immunodetection.

The present invention provides a cosmetic composition for inhibiting or improving seborrhea and a pharmaceutical composition for preventing, improving or treating seborrhea, each composition comprising a specific peptide as an active ingredient. The peptide remarkably decreases the interaction between p53 and MDM2 and thus remarkably increases the interaction between p53 and RNA Polymerase II (POLII), thereby being able to induce expressions of the cytokines that cause apoptosis of sebocytes.

This invention discloses a rutin-containing composition and its applications, belonging to the field of drug development technology. Through molecular docking simulations, animal experiments, and cell experiments, this invention demonstrates that rutin exerts its detoxification effect through a dual mechanism: firstly, it antagonizes the inhibitory effect of α-amatoxins on RNA polymerase II, improving transcriptional repression induced by poisoning; secondly, it alleviates oxidative stress caused by α-amatoxins, reducing MDA content and increasing SOD activity. Rutin significantly improves the survival rate of mice poisoned by α-amatoxins, improves hepatocellular pathological damage, and reduces liver function indicators AST and ALT levels. The optimal dosage is 175 mg / kg, indicating that rutin can be considered a potential therapeutic drug for α-amatoxins poisoning. This invention provides a new treatment option for α-amatoxins poisoning. Rutin is a marketed drug with guaranteed safety and significant advantages for clinical translation.

The invention relates to application of RNA polymerase II subunit C as a gastric cancer treatment target. Specifically, the invention provides an application of an inhibitor of RNA polymerase II subunit C (POLR2C) in preparation of a product for inhibiting proliferation, metastasis and / or invasion of gastric cancer cells, in particular an application in a drug for treating gastric cancer. Also provided herein are products that inhibit gastric cancer cell proliferation, metastasis and / or invasion.